UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013807
Receipt number R000015336
Scientific Title Long-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failure
Date of disclosure of the study information 2014/04/25
Last modified on 2017/07/23 07:52:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Long-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failure

Acronym

Clinical Effect of Long-term Tolvaptan Administration

Scientific Title

Long-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failure

Scientific Title:Acronym

Clinical Effect of Long-term Tolvaptan Administration

Region

Japan


Condition

Condition

heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the clinical effect of long-term Tolvaptan administration in patients with heart failure with fluid retention. Especially, to examine the effects of neurohormonal factors and renal function.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The changes in neurohormonal factors (catecholamine, renin activity, aldosterone, copeptin)

Key secondary outcomes

The finding of fluid retention, the changes in serum sodium, BUN, Cr, urinary L-FABP, dosage of diuretics, blood pressure, heart rate and 6-month prognosis (readmission and death)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Assigned following 2 groups, when heart failure treatment is hemodynamically stable.
TLV group: Add on tolvaptan (1.875mg/day to 15mg/day) with conventional diuretics for 6 months.

Interventions/Control_2

Conventinal diuretics group: Treat with conventional diuretics except tolvaptan for 6 months.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Heart failure in-hospital patients with fluid retention
Required continuous diuretics treatment

Key exclusion criteria

Patients with a history of hypersensitivity for tolvaptan or an analogue.
Anuresis or hypernatremia.
Patients who have difficulty with fluid intake or can not feel dipsesis.
Pregnant woman or possibility of the pregnancy.
Patients whom tolvaptan is already given at registration.
Patients whom study responsibility physician judged inappropriate.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kiyoshi Iida

Organization

Nihon University Surugadai Hospital

Division name

Department of Cardiology

Zip code


Address

1-8-13 Kanda-Surugadai, Chiyoda, Tokyo

TEL

03-3293-1711

Email

kiida2830@jcom.home.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kiyoshi Iida

Organization

Nihon University Surugadai Hospital

Division name

Department of Cardiology

Zip code


Address

1-8-13 Kanda-Surugadai, Chiyoda, Tokyo

TEL

03-3293-1711

Homepage URL


Email

kiida2830@jcom.home.ne.jp


Sponsor or person

Institute

Nihon University Surugadai Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

駿河台日本大学病院(東京都)、日本大学板橋病院(東京都)、聖路加国際病院(東京都)、三井記念病院(東京都)


Other administrative information

Date of disclosure of the study information

2014 Year 04 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 03 Month 09 Day

Date of IRB


Anticipated trial start date

2014 Year 03 Month 20 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 04 Month 25 Day

Last modified on

2017 Year 07 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015336


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name